InhaTarget Therapeutics
We support InhaTarget Therapeutics, a spin-off from ULB dedicated to developing innovative inhalation-based treatments for pulmonary diseases, with a particular focus on lung cancer.
Founded in 2019, InhaTarget brings together deep expertise in drug formulation, inhalation delivery, and clinical operations to redefine existing molecules through novel therapeutic approaches.
Discover More